Charlotte E Costentin1, Cristina R Ferrone2, Ronald S Arellano3, Suvranu Ganguli3, Theodore S Hong4, Andrew X Zhu1. 1. Massachusetts General Hospital Cancer Center, Harvard Medical School, Boston, Massachusetts, USA. 2. Department of Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 3. Department of Radiology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, USA. 4. Department of Radiation Oncology, Massachusetts General Hospital, Boston, Massachusetts, USA.
Abstract
BACKGROUND: Tumoral macrovascular invasion (MVI) of hepatic and/or portal vein branches is a common phenomenon in hepatocellular carcinoma (HCC) and is associated with poorer prognosis when compared to HCC without MVI. SUMMARY: Current international guidelines for the management of HCC recommend sorafenib as the only treatment option in case of MVI. Despite guideline recommendations, several alternative options have been tested to manage HCC with MVI: surgery, transarterial chemoembolization, external or internal radiation, hepatic arterial infusion chemotherapy, percutaneous treatment, cryotherapy, or the combination of two or more of these strategies, with or without sorafenib. Here we will provide a comprehensive state-of-the-art review for the management of this challenging clinical entity based on the most recent available data. KEY MESSAGES: There is a growing body of evidence suggesting that alternative strategies to standard-of-care sorafenib might improve survival in patients with advanced HCC with MVI but the level of evidence remains weak. Randomized phase III trials are ongoing and will hopefully provide information leading towards a more personalized treatment algorithm.
BACKGROUND: Tumoral macrovascular invasion (MVI) of hepatic and/or portal vein branches is a common phenomenon in hepatocellular carcinoma (HCC) and is associated with poorer prognosis when compared to HCC without MVI. SUMMARY: Current international guidelines for the management of HCC recommend sorafenib as the only treatment option in case of MVI. Despite guideline recommendations, several alternative options have been tested to manage HCC with MVI: surgery, transarterial chemoembolization, external or internal radiation, hepatic arterial infusion chemotherapy, percutaneous treatment, cryotherapy, or the combination of two or more of these strategies, with or without sorafenib. Here we will provide a comprehensive state-of-the-art review for the management of this challenging clinical entity based on the most recent available data. KEY MESSAGES: There is a growing body of evidence suggesting that alternative strategies to standard-of-care sorafenib might improve survival in patients with advanced HCC with MVI but the level of evidence remains weak. Randomized phase III trials are ongoing and will hopefully provide information leading towards a more personalized treatment algorithm.
Authors: Gi-Ae Kim; Ju Hyun Shim; Sang Min Yoon; Jinhong Jung; Jong Hoon Kim; Min-Hee Ryu; Baek-Yeol Ryoo; Yoon-Koo Kang; Danbi Lee; Kang Mo Kim; Young-Suk Lim; Han Chu Lee; Young-Hwa Chung; Yung Sang Lee Journal: J Vasc Interv Radiol Date: 2015-01-19 Impact factor: 3.464
Authors: Do Seon Song; Myeong Jun Song; Si Hyun Bae; Woo Jin Chung; Jae Young Jang; Young Seok Kim; Sae Hwan Lee; Jun Yong Park; Hyung Joon Yim; Sung Bum Cho; Soo Young Park; Jin Mo Yang Journal: J Gastroenterol Date: 2014-07-16 Impact factor: 6.772
Authors: Young Youn Cho; Minjong Lee; Hyo-Cheol Kim; Jin Wook Chung; Yun Hwan Kim; Geum-Youn Gwak; Si Hyun Bae; Do Young Kim; Jeong Heo; Yoon Jun Kim Journal: PLoS One Date: 2016-05-05 Impact factor: 3.240
Authors: Jennifer L Steel; Lauren Terhorst; Kevin P Collins; David A Geller; Yoram Vodovotz; Juliana Kim; Andrew Krane; Michael Antoni; James W Marsh; Lora E Burke; Lisa H Butterfield; Frank J Penedo; Daniel J Buysse; Allan Tsung Journal: Psychosom Med Date: 2018-06 Impact factor: 4.312
Authors: Joseph C Ahn; Marie Lauzon; Michael Luu; Marc L Friedman; Kambiz Kosari; Nicholas Nissen; Shelly C Lu; Lewis R Roberts; Amit G Singal; Ju Dong Yang Journal: J Nucl Med Date: 2021-04-09 Impact factor: 11.082